More about Deep Genomics

NJF Capital presents Deep Genomics.

Creating a universe of genetic medicines, Deep Genomics is already the leader to rule drug development with data and AI. Drug development has traditionally been a complicated and laborious process dominated by serendipity. AI and machine learning enable a systematic, efficient, and reliable approach where wet-lab experiments confirm high-confidence hypotheses. Deep Genomics models trained to predict cell biology can reveal the molecular phenotype of disease-causing mutations. By predicting a reversal of such molecular phenotype, compounds that address therapeutic needs can be identified from which genetic medicines can be potentially predicted.

Deep Genomics is formed by a team of internationally recognised experts in AI, Machine Learning, biology, chemistry, drug development, rare disease, genetics, automation and software. Deep Genomics plans to develop new systems to address 10 times more patients every two years.

Deep Genomics in the news